5-fluorouracil and low-dose recombinant interferon-α-2a in patients with hormone-refractory adenocarcinoma of the prostate

Prostate

Volumn 35, Issue 1, 1998, Pages 56-62

  Shinohara, Nobuo ^a   Demura, Takayoshi ^a   Matsumura, Kin Ya ^a   Toyoda, Ken Ichi ^a   Kashiwagi, Akira ^a   Nagamori, Satoshi ^b   Ohmuro, Hiroshi ^b   Ohzono, Sei Ichirou ^c   Koyanagi, Tomohiko ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO CANCER CENTER   (Japan)

^c NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

5 FU; Chemotherapy; Hormone refractory; Interferon; Prostate cancer

Indexed keywords

ANTIANDROGEN; CHLORMADINONE ACETATE; CISPLATIN; ESTRAMUSTINE PHOSPHATE; ESTROGEN; FLUOROURACIL; FLUTAMIDE; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT ALPHA2A INTERFERON; UFT;

ADULT; AGED; ANOREXIA; ARTICLE; BOLUS INJECTION; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG RESPONSE; GASTROINTESTINAL TOXICITY; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; THROMBOCYTOPENIA;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAMUSCULAR; INTERFERON ALFA-2A; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 0031946417     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19980401)35:1<56::AID-PROS8>3.0.CO;2-F     Document Type: Article

References (21)

1. Huggins C, Hodges CV: Studies on prostate cancer. 1. The effect of castration, of estrogen, and androgen injection on serum phosphates in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-297.
2. Labrie F, Dupont A, Belanger A: Complete androgen blockade for the treatment of prostate cancer. In Devita VT Jr, Hellman S, Rosenberg SA (eds): "Important Advances in Oncology." Philadelphia: JB Lippincott, 1985, pp 193-217.
3. de Kernion JN, Murphy GP, Priore R: Comparison of flutamide and emcyt in hormone refractory prostatic cancer. Urology 1988; 31:312-317.
4. Eisenberger MA, Simon R, O'Dwyer PJ, Wittes RE, Friedman MA: A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 1985;3:827-841.
5. Scher HI, Curley T, Yeh S, Iversen JM, O'Dell M, Larson SM: Therapeutic alternatives for hormone-refractory prostatic cancer. Semin Urol 1992;10:55-64.
6. Kuzel TM, Tallman MS, Shevrin D, Braud E, Kilton L, Johnson P, Kozlowski J, Vogelzang NJ, Blough R, Benson III AB: A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer; an Illinois Cancer Center Study. Cancer 1993;72:1965-1968.
7. Wadler S, Schwarts EL, Goldman M, Lyver A, Rader M, Zimmerman M, Lyri L, Weinberg V, Wiernik PH: Fluorouracil and recombinant alpha-2a interferon; an active regimen against advanced colorectal carcinoma. J Clin Oncol 1989;7:1769-1775.
8. Dreicer R, Forest PK, Williams RD: Phase II trial of 5-fluorouracil and α-2b interferon in patients with hormone-refractory metastatic prostate cancer. Urology 1994;44:377-380.
9. Daliani DD, Eisenberg PD, Weems J, Lord R, Fueger R, Logothetis CJ: The results of a phase II randomized trial comparing 5-fluorouracil and 5-fluorouracil plus α-interferon: Observations on the design of clinical trials for androgen-independent prostate cancer. J Urol 1995;153:1587-1591.
10. Shinohara N, Harabayashi T, Matsuda H, Nounaka O, Nonomura K, Koyanagi T, Nagamori S, Ohmuro H, Matsumura K, Demura T: 5-Fluorouracil and alpha-2a interferon in patients with hormone-refractory prostate cancer. Jpn J Urol 1995;86: 1557-1562.
11. Murphy GP, Slack NH: Response criteria for the prostate of the USA National Prostatic Cancer Project. Prostate 1980;1:375-382.
12. Millar A, Hoogstraten B, Staquent M, Winkler A: Reporting results of cancer treatment. Cancer 1981;47:207-214.
13. Kaplan E, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
14. Saroff J, Kirdani R, Yamanaka II, Murphy GP, Sandberg AA: A possible model for drugs in prostatic carcinoma. Proc Am Assoc Cancer Res 1973;14:13 (abst).
15. Eisenberger MA: Chemotherapy for endocrine resistant cancer of the prostate. Prog Clin Biol Res 1990;359:155-164.
16. van Haelst-Pisani CM, Richardson RL, Su J, Buckner JC, Hahn RG, Frytak S, Kvols LK, Burch PA: A phase II study of recombinant human alpha-interferon in advanced hormone-refractory prostate cancer. Cancer 1992;70:2311-2312.
17. Grem JL, van Groeningen CJ, Ismail AA, Johnston PG, Alexander HR, Allegra CJ: The role of interferon-alpha as a modulator of fluorouracil and leucovorin. Eur J Cancer 1995;31A: 1316-1320.
18. Wadler S, Schwartz EL, Goldman M: Preclinical and clinical studies of 5-fluorouracil (Fura) and recombinant alpha-2a interferon (IFN) against gastrointestinal (GI) malignancies. Clin Res 1988;36:803A (abst).
19. Ragnhammer P, Blomgren II, Edler D, Lundell G, Magnusson I, Sonnenfeld T: Different dose regimens of 5-fluorouracil and interferon-alpha in patients with metastatic colorectal carcinoma. Eur J Cancer 1995;31A:315-320.
20. Czejka MJ, Schuller J, Jager W, Fogl U, Weiss C: Influence of different doses of interferon-alpha-2b on the blood plasma levels of 5-fluorouracil. Eur J Drug Metab Pharmacokinetics 1993; 18:247-250.
21. Glazier DB, Heaney JA, Amdur RJ, Schned AR, Harris R, Fukui I, Ernstoff MS: 5-Fluorouracil and allopurinol combined with recombinant interferon-α2b in the treatment of patients with advanced prostate cancer: A phase I/II study. J Urol 1996;155: 624-627.